J0893 — Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg
J0893 is a HCPCS Level II code for injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg. It belongs to the Drugs Administered Other Than Oral Method section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusE
Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for J0893
- Long descriptor
- Injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg
- Short descriptor
- Inj, decitabine (sun pharma)
- Added
- January 1, 2023
- BETOS
- O1E
- Pricing indicator
- 51 — Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Drugs.
Codes adjacent to J0893
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If J0893 is not quite right, the correct code is very often within a few positions of it.
- J0885Injection, epoetin alfa, (for non-esrd use), 1000 units
- J0886Injection, epoetin alfa, 1000 units (for esrd on dialysis)terminated
- J0887Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
- J0888Injection, epoetin beta, 1 microgram, (for non esrd use)
- J0889Daprodustat, oral, 1 mg, (for esrd on dialysis)terminated
- J0890Injection, peginesatide, 0.1 mg (for esrd on dialysis)
- J0891Injection, argatroban (accord), not therapeutically equivalent to j0883, 1 mg (for non-esrd use)
- J0892Injection, argatroban (accord), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis)
- J0894Injection, decitabine, 1 mg
- J0895Injection, deferoxamine mesylate, 500 mg
- J0896Injection, luspatercept-aamt, 0.25 mg
- J0897Injection, denosumab, 1 mg
- J0898Injection, argatroban (auromedics), not therapeutically equivalent to j0883, 1 mg (for non-esrd use)
- J0899Injection, argatroban (auromedics), not therapeutically equivalent to j0884, 1 mg (for esrd on dialysis)
- J0900Injection, testosterone enanthate and estradiol valerate, up to 1 ccterminated
- J0901Vadadustat, oral, 1 mg (for esrd on dialysis)
Questions about J0893
What is HCPCS code J0893?
J0893 is a HCPCS Level II code for injection, decitabine (sun pharma), not therapeutically equivalent to j0894, 1 mg. It sits in the Drugs Administered Other Than Oral Method section.
Does Medicare cover J0893?
The CMS HCPCS file marks J0893 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
How is J0893 paid under the physician fee schedule?
J0893 carries PFS status code E. Excluded from the physician fee schedule by regulation. Payment, where it exists, comes from another fee schedule (drugs via ASP, supplies via DMEPOS, and so on).